Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 3/20 | 0.67 |
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.67 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.67 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.67 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.67 |
| ▸ | POLG | P54098 | 3/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.40 |
| ▸ | ST6GAL1 | P15907 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.39 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.39 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.39 |
| ▸ | PPM1B | O75688 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6448105 | 1.00 | ALB (0.67) | ALBLMNAPDE3ACACNA1FMAPT | |
| SCHEMBL9195439 | 1.00 | ALB (0.67) | ALBLMNAPDE3ACACNA1FMAPT | |
| SCHEMBL9195454 | 1.00 | ALB (0.67) | ALBLMNAPDE3ACACNA1FMAPT | |
| SCHEMBL7932120 | 1.00 | ALB (0.67) | ALBLMNAPDE3ACACNA1FMAPT | |
| SCHEMBL1389107 | 0.89 | ALB (0.61) | ALBLMNAPDE3ACACNA1FMAPT | |
| Water SCHEMBL3460531 | 0.88 | ALB (0.60) | ALBLMNAPDE3ACACNA1FMAPT | |
| SCHEMBL14580363 | 0.87 | ALB (0.70) | ALBLMNAPDE3ACACNA1FMAPT | |
| SCHEMBL9719001 | 0.85 | ALB (0.47) | ALBLMNAPDE3ACACNA1FMAPT | |
| SCHEMBL598860 | 0.85 | POLG (0.66) | ALBLMNAPDE3ACACNA1FMAPT | |
| SCHEMBL23788550 | 0.85 | ALB (0.76) | ALBLMNAPDE3ACACNA1FMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050250950-A1 | 1,3-oxathiolane nucleoside analogues | SHIRE CANADA INC. (CA) | 2005-11-10 | — | — | US | disclosed |
| US-20030004175-A1 | 1,3-oxathiolane nucleoside analogues | BIOCHEM PHARMA INC. (CA) | 2003-01-02 | — | — | US | disclosed |
| EP-0517145-B1 | Crystalline oxathiolane derivatives | GLAXO GROUP LTD (GB) | 2002-01-30 | — | — | EP | disclosed |
| EP-1099700-A1 | Crystalline oxathiolane derivatives | GLAXO GROUP LIMITED (GB) | 2001-05-16 | — | — | EP | disclosed |
| EP-1062950-A2 | 1,3 Oxathiolane nucleoside analogues | BIOCHEM PHARMA INC (CA) | 2000-12-27 | — | — | EP | disclosed |
| US-5905082-A | TREATING HIV IN HUMANS | GLAXO GROUP LIMITED (GB) | 1999-05-18 | — | — | US | disclosed |
| US-5859021-A | SYNERGISTIC ANTI-HIV MIXTURE OF COMPOUNDS (2R, CIS)-4-AMINO-1-(2-HYDROXY-METHYL-1,3-OXATHIOLAN-5-YL)-1 H-PYRIMIDIN-2-ONE AND 3*-AZIDO-3*-DEOXYTHYMIDINE (AZT) OR THEIR SALTS AND ESTERS; NO INCREASE IN CYTOTOXICITY | GLAXO GROUP LIMITED (GB) | 1999-01-12 | — | — | US | disclosed |
| US-5627186-A | Antiviral combinations | GLAXO GROUP LIMITED (GB) | 1997-05-06 | — | — | US | disclosed |
| EP-0513917-B1 | Antiviral combinations containing nucleoside analogs | GLAXO GROUP LTD (GB) | 1995-12-20 | — | — | EP | disclosed |
| EP-0674634-A1 | PROCESS FOR PREPARING SUBSTITUTED 1,3-OXATHIOLANES WITH ANTIVIRAL PROPERTIES | BIOCHEM PHARMA INC (CA) | 1995-10-04 | — | — | EP | disclosed |
| WO-1992021676-A1 | CRYSTALLINE OXATHIOLANE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1992-12-10 | — | — | WO | disclosed |
| EP-0517145-A1 | Crystalline oxathiolane derivatives | GLAXO GROUP LIMITED (GB) | 1992-12-09 | — | — | EP | disclosed |
| WO-1992020344-A1 | ANTIVIRAL COMBINATIONS CONTAINING NUCLEOSIDE ANALOGS | GLAXO GROUP LIMITED (GB) | 1992-11-26 | — | — | WO | disclosed |
| WO-1991017159-A1 | 1,3-OXATHIOLANE NUCLEOSIDE ANALOGUES | IAF BIOCHEM INTERNATIONAL INC. (CA) | 1991-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004175-A1 | 1,3-oxathiolane nucleoside analogues | TYMP, PNP, MTAP | ALB 1882/4885LMNA 1664/4885PDE3A 728/4885 |
| US-20050250950-A1 | 1,3-oxathiolane nucleoside analogues | TYMP, PNP, NUDT1 | ALB 1696/4885LMNA 1866/4885PDE3A 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.